Abstract: TH-PO182
Levels of Oxidative Stress and Inflammation in Different Degrees of Diabetic Kidney Disease Caused by Diabetes Mellitus Type 2
Session Information
- Diabetic Kidney Disease: Clinical - I
November 02, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Diabetic Kidney Disease
- 702 Diabetic Kidney Disease: Clinical
Authors
- Gutiérrez Hernandez, José Jesús, Instituto Mexicano del Seguro Social, Ciudad de Mexico, Guadalajara, Mexico
- Salazar Soltero, Luis Alberto, Instituto Mexicano del Seguro Social, Ciudad de Mexico, Guadalajara, Mexico
- Soto-Vargas, Javier, Instituto Mexicano del Seguro Social, Ciudad de Mexico, Guadalajara, Mexico
- Romero Tafoya, Juan Oziel, Instituto Mexicano del Seguro Social, Ciudad de Mexico, Guadalajara, Mexico
- Espinoza, Hugo Bonifacio, Instituto Mexicano del Seguro Social, Ciudad de Mexico, Guadalajara, Mexico
- Villanueva Macedo, Roxana, Instituto Mexicano del Seguro Social, Ciudad de Mexico, Guadalajara, Mexico
- De Niz Hernández, Paulina, Instituto Mexicano del Seguro Social, Ciudad de Mexico, Guadalajara, Mexico
- Parra Michel, Renato, Instituto Mexicano del Seguro Social, Ciudad de Mexico, Guadalajara, Mexico
Background
Chronic inflammation is related to its progression and cardiovascular and infectious complications, alterations in the immune response, which translates into a greater risk of morbidity and mortality. Oxidative stress is considered a non-traditional risk factor for all causes of mortality, considering it a prognostic factor and a target for the prevention and treatment of CKD.
Methods
Retrospective observational descriptive study in adult patients >18 years of age, with type 2 Diabetes Mellitus (DM2) and CKD grades 1 5 according to the KDIGO, who attended the Nephrology clinic at the IMSS HGR46. We evaluate the levels of oxidative stress and inflammation in the different degrees of diabetic kidney disease in patients with DM2.
Results
We included 80 patients diagnosed with diabetic CKD were included and the serum levels of Superoxide dismutase SOD and Malondialdehyde MDA were determined. We classified according to the severity of the disease using KDIGO based on eGFR into three groups: patients with mild , moderate and severe. Plasma SOD levels were determined in patients with CKD; the average SOD was 2.07 ± 0.64. According to the severity of the CKD, no significant differences were identified p=0.46, although there were numerical differences with a tendency to lower levels in patients with severe CKD. Regarding MDA, a significant difference was observed in the levels according to the severity of the CKD. With higher levels in patients with mild CKD, and with lower levels according to the severity of the disease p=0.003.
Conclusion
Serum levels of SOD and MDA seem to reduce as eGFR decreases, being higher in the mild disease group, which may be related to greater inflammation at the onset of CKD.
Funding
- Government Support – Non-U.S.